Results 21 to 30 of about 655,147 (306)

Expedited surgery does not increase transfusion rates for patients with geriatric hip fracture taking factor Xa inhibitors [PDF]

OTA International, 2023
. Objectives:. Geriatric patients who sustain hip fractures and are taking factor Xa inhibitors (Xa-I) experience surgical delay. Our institution developed a pharmacokinetic protocol to formally guide and expedite surgical timing for these patients.
Juntian Wang, MD, Paal Nilssen, BS, Julia Stone, BS, Kathleen Breda, MSN, BBA, RN, AGACNP-BC, ONP-C, Milton Little, MD, Charles Moon, MD, Carol Lin, MD   +6 more
doaj   +2 more sources

Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors [PDF]

TH Open
Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniella Defonte, Kanta Ochani, Amanda Lin, Bhumi Patel, Nikolaos Tsaftaridis, Jack Jnani, Alex C. Spyropoulos   +16 more
doaj   +2 more sources

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved]

F1000Research, 2021
Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Ardyan Wardhana, Johanes Nugroho Eko Putranto, Pirhot Lambok Marnala Yosua Siahaan, Yoga Alfian Noor, Makhyan Jibril Al Farabi   +4 more
doaj   +1 more source

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Circulation, 2023
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b ...
T. Milling, S. Middeldorp, Lizhen Xu, Bruce R Koch, A. Demchuk, J. Eikelboom, P. Verhamme, A. Cohen, J. Beyer-Westendorf, C. Michael Gibson, J. López-Sendón, M. Crowther, A. Shoamanesh, M. Coppens, Jeannot Schmidt, P. Albaladéjo, S. Connolly, R. Anand, A. Bastani, C. Clark, M. Concha, J. Cornell, K. Dombrowski, G. Fermann, J. Fulmer, J. Goldstein, D. Kereiakes, T. Milling, D. Pallin, N. Patel, M. Refaai, M. Rehman, A. Schmaier, E. Schwarz, W. Shillinglaw, M. Spohn, T. Takata, A. Venkat, J. Welker, I. Welsby, J. Wilson, L. Van Keer, F. Verschuren, M. Blostein, J. Eikelboom, K. Althaus, J. Berrouschot, G. Braun, T. Doeppner, R. Dziewas, S. Genth‐Zotz, P. Greinacher, F. Hamann, F. Hanses, W. Heide, B. Kallmuenzer, P. Kermer, S. Poli, G. Royl, S. Schellong, S. Schnupp, J. Schwarze, C. Spies, G. Thomalla, M. von Mering, K. Weissenborn, F. Wollenweber, C. Gumbinger, U. Jaschinski, M. Maschke, H. Mochmann, W. Pfeilschifter, C. Pohlmann, R. Zahn, P. Bouzat, J. Schmidt, C. Vallejo, B. Floccard, M. Coppens, S. V. van Wissen, E. Arellano-Rodrigo, E. Vallès, R. Alikhan, K. Breen, R. Hall, M. Crowther, P. Albaladéjo, A. Cohen, A. Demchuk, D. Wyse, D. A. Garcia, M. Prins, J. Nakamya, H. Büller, K. Mahaffey, J. Alexander, J. Cairns, R. Hart, C. Joyner, G. Raskob, S. Schulman, R. Veltkamp, B. Meeks, E. Zotova, Sahar Ahmad, T. Pinto, K. Baker, A. Dykstra, I. Holadyk-Gris, Antonio Malvaso   +109 more
semanticscholar   +1 more source

Prediction of inhibition constants of (R)-3-amidinophenylalanine inhibitors toward factor Xa by 2D-QSAR model

Vietnam Journal of Science, Technology and Engineering, 2022
A coagulation cascade forms through proteolytic reactions and involves different factors. There are two coagulation pathways, including intrinsic and extrinsic mechanisms, which converge by the formation of factor Xa.
Thi Bich Van Pham, Minh Hao Hoang
doaj   +1 more source

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis

eNeurologicalSci, 2022
Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs ...
Alexei Christodoulides, Bradley N. Bohnstedt   +1 more
doaj   +1 more source

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa

International Journal of Laboratory Hematology, 2021
Andexanet alfa (AnXa) was developed for anticoagulant effect reversal of direct factor Xa inhibitors (DXaI) (apixaban, rivaroxaban, edoxaban) in emergency situations.
Matthieu Bourdin, Delphine Perrotin, O. Mathieu, Tristan Hervé, F. Depasse, Genmin Lu, P. Conley, G. Contant   +7 more
semanticscholar   +1 more source

Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile [PDF]

, 2016
Factor XIIIa (FXIIIa) is a transglutaminase that catalyzes the last step in the coagulation process. Orthostery is the only approach that has been exploited to design FXIIIa inhibitors.
Afosa, Daniel K., Al-Horani, Rami A., Desai, Umesh R., Karuturi, Rajesh, Lee, Michael   +4 more
core   +7 more sources

Anticoagulation by factor Xa inhibitors [PDF]

Journal of Thrombosis and Haemostasis, 2010
Therapeutic agents that regulate blood coagulation are critical to the management of thrombotic disorders, with the selective targeting of factor (F) Xa emerging as a promising approach.To assess anticoagulant strategies targeting FXa.A deterministic computational model of tissue factor (Tf)-initiated thrombin generation and two empirical experimental ...
T, Orfeo, S, Butenas, K E, Brummel-Ziedins, M, Gissel, K G, Mann   +4 more
openaire   +2 more sources

Study Of Phenothiazine On p53 Core Domain Mutant Y220C: Finding The Anti-tumor Activity Of Phenothiazine [PDF]

, 2011
The tumor suppressor protein p53 is a transcription factor that plays a key role in the prevention of cancer development. The p53 cancer mutation Y220C induces formation of a cavity on the protein's surface that can accommodate stabilizing small ...
Asif Husain Naqvi, Hardik H. Sheth, Suchindran H S, Vijay Kumar, Vivek Gupta   +4 more
core   +2 more sources